Últimas noticias sobre Fastly (NYSE:FSLY) Bolsa

Fastly

Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

COIN

FSLY

GEHC

HUBS

Wall Street anticipa importantes reportes financieros. Expectativas para Deere, Fastly, GE HealthCare y HubSpot y Coinbase.

Acciones a seguir en Wall Street hoy: Deere, Fastly, GE HealthCare y más

Media

ATEN

IESC

Jim Cramer analiza el rendimiento de varias acciones estadounidenses y comparte sus recomendaciones clave. ¿Cuáles destacan y cuáles evitar?

Cramer respalda NextEra Energy (NEE) y descarta otras acciones: ¿cuáles tienen más potencial?

Fastly Inc

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)&nbsp;disclosed in its 2024 annual report last week that the <a target="_blank" href="https://www.benzinga.com/topic/tsm" rel="noreferrer noopener">U.S. semiconductor technology</a> embargo challenged its ability to ensure complete compliance with the rules.
The Taiwanese contract chipmaker also held the semiconductor sanctions responsible for leading to higher violations of semiconductor sanctions by business partners to gain access to <a target="_blank" href="https://investor.tsmc.com/english/annual-reports" rel="noreferrer noopener">the advanced technology</a>.
Taiwan Semiconductor disclosed it could not guarantee complete compliance.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst" rel="noreferrer noopener">These Semiconductor Stocks To Face Least Tariffs Impact Compared To Intel</a>
Taiwan Semiconductor partners&nbsp;Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)&nbsp;and&nbsp;MediaTek Inc co-developed mobile chips for phone makers, including&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), as per a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-21/tsmc-warns-of-limits-of-ability-to-keep-its-ai-chips-from-china?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">report</a>. However, a 2024 report by TechInsights&nbsp;revealed&nbsp;the presence of Taiwan Semiconductor technology in Huawei Technology&#8217;s Ascend 910B AI chip.
The U.S. has restricted Huawei&#8217;s access to advanced semiconductor technology since 2020, citing national security threats.
Taiwan Semiconductor disclosed in its annual report that it took every precaution, including restricting shipment to its trading partners, to ensure compliance with the U.S. sanctions.
Taiwan Semiconductor&#8217;s <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">first-quarter revenue</a> rose 41.6% to $25.53 billion, topping the analyst consensus estimate of $23.92 billion, despite a smartphone seasonality impact on sales.
The second-quarter revenue guidance predicts $28.4 billion-$29.2 billion versus the $26.79&nbsp;billion analyst estimate, with strong demand for 3-nm and 5-nm technologies.
In March, Taiwan Semiconductor announced&nbsp;an additional&nbsp;$100 billion&nbsp;investment&nbsp;in U.S. chipmaking (on top of $65 billion in April 2024). The investment followed&nbsp;President Donald Trump&#8217;s verbal attacks&nbsp;on Taiwan &#8220;for stealing&#8221; the U.S. semiconductor business and generating massive trade deficits for Washington.
Price Action:&nbsp;TSM stock is down by 1.91% to $148.85 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44851295/asml-cfo-incorporates-tariff-impact-in-outlook-reveals-strong-demand-for-advanced-euv-and-high-na-systems" target="_blank" rel="noreferrer noopener">ASML CFO Incorporates Tariff Impact In Outlook, Reveals Strong Demand For Advanced EUV And High NA Systems</a></li>
</ul>
Photo by Sundry Photography on Shutterstock

Asia

Government

Regulations

Tech

QCOM

XIACF

XIACY

Taiwan Semiconductor Confronts Challenges Of US Chips Sanction On China

Native health advocates are raising alarms over a proposed federal budget that reduces funding to the Indian Health Service (IHS). In a letter dated April 17 sent to the Health and Human Services Secretary Robert F. Kennedy, Jr., the National Indian Health Board (NIHB) criticized the planned cuts as dangerous and urged urgent rectification.
What Happened: The Office of Management and Budget's (OMB) proposed adjustments include almost a 30% reduction to the IHS base budget from FY 2025 estimates, amounting to approximately $900 million in cuts for FY 2026. The plan also removes advance appropriations, stops funding for water and sanitation and healthcare facility construction, restricts self-governance for new Tribes, and eradicates services across the board.
"We implore you to immediately appeal the proposed reductions… mirroring the swift and decisive action taken by the Secretary of the Interior," the NIHB urged <a href="https://ncuih.org/2025/04/18/ncuih-urges-hhs-to-reconsider-proposed-budget-cuts-to-indian-health-service-and-hhs/">in the letter</a>.
See Also: <a href="https://www.benzinga.com/25/03/44514142/rfk-jr-to-announce-10000-job-cuts-shut-regional-agencies-in-a-major-health-department-overhaul-report">RFK Jr. To Cut 10,000 Jobs, Shut Regional Agencies In Major Health Department Overhaul: Report</a>
Why It Matters: The IHS operates with a 30% vacancy rate at the moment, the letter states. It adds: "if each facility across the IHS lost just one physician-level provider, 43% of those facilities would have to close their doors entirely."
The letter calls the proposed cuts as a direct threat to life. "This loss of funding will lead to deaths in our communities from preventable medical incidents, such as precipitous births, cardiac events, untreated diabetes complications, and preventable suicides," it warns.
The NIHB clarifies that these are not hypotheticals—they are documented outcomes from past underfunding. "Before IHS had advance appropriations… members of our families died from these exact types of preventable emergencies," the letter said.
Secretary Kennedy has previously said Indian health is a top priority. With more than 574 federally recognized Tribal Nations relying on IHS, the NIHB is calling on him to that stay true to that promise by declining the OMB's proposed reductions.
"The funding to the IHS is not an arbitrary budget number," the NIHB wrote. "These figures represent funding to keep doctors and nurses in our facilities nationwide."
Kennedy Jr.&#8217;s <a href="https://www.benzinga.com/25/04/44782857/rfk-jrs-massive-federal-health-workforce-cut-could-take-decades-to-rebuild-warn-experts-we-cannot-accurately-assess-whether-we-are-truly-making-america-healthier">mass layoffs have concerned experts</a>, disrupting crucial health data collection and research, including studies on cancer in firefighters and the transmission of HIV and syphilis from mothers to babies. Attempts to monitor and contain disease outbreaks—like the country&#8217;s worst measles outbreak in decades—have also been impacted.
Earlier this month, Kennedy <a href="https://www.benzinga.com/25/04/44777309/health-secretary-kennedy-raises-concerns-about-taxpayer-funded-care-for-risky-behaviors">stirred controversy</a> in an interview with CBS News, where he asked whether taxpayers should foot the bill for those who smoke regularly or often eat unhealthy foods, like doughnuts.
Read Next: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-p">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Image Via Shutterstock

Health Care

General

Native Health Leaders Slam Trump Administration's Proposed $900M Cuts To Indian Health Service: Call Plan 'Dangerous' In Letter To RFK Jr.

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented&nbsp;
Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of IMNN-001 to treat women with newly diagnosed advanced ovarian cancer was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is being held May 30 - June 3, 2025, in Chicago, Illinois and virtually. IMUNON recently announced alignment with the U.S. Food and Drug Administration (FDA) on the study protocol for the Phase 3 OVATION 3 clinical trial of IMNN-001 and has initiated trial site activation.
IMNN-001, based on the company's proprietary TheraPlas&#xAE; technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response including overall survival benefit in frontline treatment in patients with advanced (Stage III/IV) ovarian cancer.
"We are pleased to have the opportunity to present new data from the Phase 2 OVATION 2 Study of IMNN-001 in an oral presentation at ASCO's Annual Meeting," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "This recognition underscores the significant potential of IMNN-001 to transform the treatment of women with newly diagnosed advanced ovarian cancer, an underserved population that has not seen treatment innovation in over 25 years, as we advance our Phase 3 program. We look forward to sharing more about our progress during this pivotal stage of development."
Details for the oral presentation are as follows:
Presentation Details
Title: A Phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of Paclitaxel and Carboplatin in Patients Newly Diagnosed with Advanced Epithelial Ovarian Cancer (EOC): Updated survival analysts from OVATION-2 trial
Session Title: Rapid Oral Abstract – Gynecologic Cancer
Session Date: June 3, 2025
Session Time: 8:00 AM-9:30 AM CDT

Biotech

IMNN

Imunon Announces That An Abstract Highlighting New Overall Survival Data From Phase 2 Ovation 2 Study Of Imnn-001 To Treat Women With Newly Diagnosed Advanced Ovarian Cancer Was Accepted For Oral Presentation at the 2025 American Society of Clinical Oncology Annual Meeting May 30 - June 3, 2025, In Chicago, Illinois

<h3>Gainers</h3>
<ul>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares increased by 27.8% to $0.99 during Monday's pre-market session. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock increased by 16.42% to $0.85. The company's market cap stands at $7.3 million. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) stock rose 13.11% to $5.78. The company's market cap stands at $1.1 billion. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares rose 10.47% to $0.15. The company's market cap stands at $60.3 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock rose 10.29% to $0.0. The company's market cap stands at $2.9 million. </li>
<li>Ethan Allen Interiors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) stock moved upwards by 9.35% to $28.99. The market value of their outstanding shares is at $737.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 47.1% to $3.62 during Monday's pre-market session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares fell 44.09% to $0.08. The company's market cap stands at $3.8 million. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares decreased by 13.91% to $0.2. The market value of their outstanding shares is at $28.7 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares declined by 12.25% to $0.36. The market value of their outstanding shares is at $104.2 million. </li>
<li>American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) shares decreased by 9.61% to $9.41. The market value of their outstanding shares is at $119.8 million. </li>
<li>1-800-Flowers.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) shares decreased by 8.84% to $4.85. The company's market cap stands at $309.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIEV

AOUT

FLWS

LOBO

LXEH

MKDW

NWTN

QVCGA

SHCO

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 39.2% to $1.2 during Monday's pre-market session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 13.26% to $8.88. The company's market cap stands at $14.6 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock moved upwards by 12.79% to $1.41. The company's market cap stands at $5.1 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 12.6% to $0.57. The company's market cap stands at $68.8 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock increased by 11.07% to $0.32. The market value of their outstanding shares is at $9.6 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares increased by 10.97% to $9.2. The market value of their outstanding shares is at $2.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock fell 48.3% to $0.14 during Monday's pre-market session. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares decreased by 23.02% to $1.37. The market value of their outstanding shares is at $21.1 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock fell 17.6% to $1.78. The market value of their outstanding shares is at $24.4 million. </li>
<li>Cuprina Holdings (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) shares fell 16.17% to $4.15. The market value of their outstanding shares is at $87.1 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 15.79% to $0.34. The market value of their outstanding shares is at $8.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock decreased by 13.26% to $1.96. The company's market cap stands at $3.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

ALVO

APVO

CUPR

IVVD

PRPH

PRTG

RDHL

SBFM

SNSE

SXTC

VINC

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares moved upwards by 18.7% to $0.43 during Monday's pre-market session. The company's market cap stands at $7.7 million. </li>
<li>Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) stock moved upwards by 17.07% to $2.88. The market value of their outstanding shares is at $43.6 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock increased by 15.36% to $3.68. The market value of their outstanding shares is at $46.0 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) stock moved upwards by 13.25% to $0.56. The market value of their outstanding shares is at $5.3 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares rose 9.33% to $0.19. The market value of their outstanding shares is at $37.7 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) stock rose 7.01% to $6.41. The market value of their outstanding shares is at $249.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares decreased by 64.7% to $1.82 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) shares decreased by 15.85% to $0.85. The market value of their outstanding shares is at $65.1 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares declined by 14.41% to $0.11. The company's market cap stands at $15.7 million. </li>
<li>Swvl Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>) shares declined by 13.75% to $2.51. The market value of their outstanding shares is at $26.9 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock decreased by 13.11% to $1.52. The company's market cap stands at $21.3 million. </li>
<li>Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) shares fell 13.11% to $5.04. The company's market cap stands at $66.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

BIYA

ILAG

LNZA

SPAI

SWVL

VATE

YGMZ

12 Industrials Stocks Moving In Monday's Pre-Market Session

Seaport Global analyst Michael Harrison maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Buy and lowers the price target from $34 to $31.

Price Target

Analyst Ratings

Seaport Global Maintains Buy on Element Solutions, Lowers Price Target to $31

<h3>Gainers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock moved upwards by 30.8% to $8.87 during Monday's pre-market session. The market value of their outstanding shares is at $88.4 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock increased by 10.86% to $2.55. The market value of their outstanding shares is at $32.0 million. </li>
<li>Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) shares moved upwards by 10.57% to $0.59. The company's market cap stands at $37.1 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock moved upwards by 9.83% to $1.34. The market value of their outstanding shares is at $10.9 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock moved upwards by 9.2% to $1.0. The market value of their outstanding shares is at $17.7 million. </li>
<li>Datavault AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) stock moved upwards by 6.38% to $0.87. The company's market cap stands at $53.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) stock fell 44.2% to $5.5 during Monday's pre-market session. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) stock fell 14.87% to $0.32. The market value of their outstanding shares is at $9.2 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) stock declined by 13.48% to $1.99. The market value of their outstanding shares is at $2.3 million. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) stock decreased by 12.72% to $1.03. The market value of their outstanding shares is at $163.7 million. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) shares declined by 9.15% to $0.69. The market value of their outstanding shares is at $18.2 million. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) shares fell 8.57% to $0.36. The market value of their outstanding shares is at $50.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBB

DVLT

IFBD

INUV

MLGO

Nuveen California Dividend Advantage Municipal Fund 2

PXLW

SAGT

SMSI

VIAV

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Acquisition aims to provide broader access to comprehensive testing and laboratory services for patients and physicians in North Mississippi &nbsp;
BURLINGTON, N.C. (April 21, 2025) –&nbsp;<a href="https://www.labcorp.com/">Labcorp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>),&nbsp;a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services' ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories. &nbsp; Through this acquisition, North Mississippi Health Services' patients and providers will have continuity of high-quality laboratory services and access to Labcorp's leading clinical laboratory services, robust data and digital tools.&nbsp;In addition, Labcorp will open three new patient service centers in Tupelo, West Point and Amory by mid-year to increase availability of laboratory services in North Mississippi.&nbsp;

Laboratory Corporation Of America Holdings

Reported April 18, 2025: Labcorp Acquires Select Assets Of North Mississippi Health Services' Ambulatory Outreach Laboratory Business; No Financial Terms Disclosed

Company Completes International Filings for Protection Under Patent Cooperation Treaty for Expanded Global Protection to Rapidly Identify and Map Small Lethal Threats Using AI and Drone Imagery
Safe Pro Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) ("Safe Pro" or the "Company"), a leader in artificial intelligence (AI)-powered defense and security solutions, today announced that it has completed the filing of the national phase patent applications for nearly 50 jurisdictions, claiming priority to International Patent Application No. PCT/US2023/029909, published on March 21, 2024.
The Company's IP portfolio currently includes the awarded <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsafeprogroup.com%2Fsafe-pro-awarded-us-patent-for-disruptive-ai-drone-imagery-technology-a-groundbreaking-innovation-helping-to-protect-millions-of-lives-globally%2F&amp;esheet=54240804&amp;newsitemid=20250421927903&amp;lan=en-US&amp;anchor=US+Patent+No.+12%2C146%2C729+incorporating+21+claims+made+in+the+Company%26%238217%3Bs+original+patent+application+entitled%2C+%26%238220%3BSystems+and+Methods+for+Detecting+and+Identifying+Explosives.%26%238221%3B&amp;index=1&amp;md5=6d75db99deafa929fc3253423541dc67">US Patent No. 12,146,729 incorporating 21 claims made in the Company's original patent application entitled, "Systems and Methods for Detecting and Identifying Explosives."</a> These claims cover autonomous detection, identification, and labeling of explosives in orthomosaic images using AI processing of drone imagery. Valid until 2043, the patent captures the groundbreaking nature of SpotlightAI&#x2122; and its ability to transform fields ranging from humanitarian demining, agriculture, to national defense and reconstruction. The Company has now expanded its international filings by entering in the national phase of its previously filed (and related) international application filed with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.wipo.int%2Fportal%2Fen%2F&amp;esheet=54240804&amp;newsitemid=20250421927903&amp;lan=en-US&amp;anchor=World+Intellectual+Property+Organization+%28WIPO%29&amp;index=2&amp;md5=c63d9b6f57f38e5b616b28488a220186">World Intellectual Property Organization (WIPO)</a> under the Patent Cooperation Treaty ("PCT"), in Europe (extended to include Bosnia and Herzegovina), Canada, Australia, New Zealand, Japan, Israel and Ukraine; which covers patent protection rights in 47 jurisdictions.

Safe Pro Group Completes Filing Of National Phase Patent Applications For Nearly 50 Jurisdictions

ELUT

Elutia Initiates EluPro Registry Study To Collect Patient Outcome Data

Chipotle Signs Agreement With Restaurant Operator Alsea To Open Restaurants In Mexico, Beginning With A Location By Early 2026

- Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline -
- Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and services to bring innovative mental health treatments to patients in need -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54239475&amp;newsitemid=20250416179232&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=d22113092709043bd0460cb33277a431">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need.
"Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with Osmind will help us accelerate our goals," said Doug Drysdale, Chief Executive Officer of Cybin. "Osmind's extensive network of over 800 psychiatry clinics in the U.S., combined with our expertise, allows us to align on and prepare for the operational infrastructure needs relevant for interventional treatments. End-to-end mapping in key areas of clinic workflow and patients' journey such as pharmacy, fulfillment, patient access and reimbursement will lay the groundwork for commercialization of our lead clinical programs: CYB003 in Phase 3 development for the adjunctive treatment of major depressive disorder, and CYB004 in a Phase 2 study for generalized anxiety disorder. We look forward to a productive collaboration that leads to meaningful progress in transforming the treatment paradigm for patients with mental health disorders."
With 52.9 million people in the U.S., or nearly one in five Americans1, living with a mental illness, there remains a significant unmet need in addressing the mental health crisis. Many patients do not experience relief with the standard of care, highlighting a need for innovation and improved therapeutic options.
"We are thrilled to partner with Cybin; together, we are aligning incentives across stakeholders to help patients in need," said Jimmy Qian, President of Osmind. "By preparing real-world care settings for next-generation neuropsychiatric interventions, Osmind is reducing friction and promoting practice success for clinicians, increasing access for patients, while supporting Cybin's market penetration and commercial launch. Osmind and Cybin share a common mission to scale cutting-edge mental health treatments to as many patients as possible. We are delighted to support Cybin's differentiated research, development, and commercialization efforts."
Opportunity to Address Unmet Needs in Mental Health
<ul>
<li>Globally, it is estimated that over 300 million people suffer from major depressive disorder (MDD)2. The global market size for major depressive disorder was estimated at $5.15 billion in 2024 and is projected to rise to $11.09 billion by 2033.3</li>
<li>An estimated 21 million Americans experienced at least one major depressive episode in 2021.4 About two-thirds of patients with MDD do not experience relief with initial antidepressant treatment.5</li>
<li>It is estimated that 6.8 million people in the U.S. suffer from generalized anxiety disorder ("GAD").6 Approximately 50% of patients with GAD are unresponsive to first line treatment with selective serotonin reuptake inhibitors ("SSRIs") and serotonin-norepinephrine reuptake inhibitors ("SNRIs").7</li>
</ul>

Contracts

CYBN

Cybin Entyers Strategic Partnership With Osmind To Help Bring Innovative Mental Health Treatments To Patients In Need

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) announced on Monday that it is stepping deeper into the floral business with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44893128/target-launches-new-fresh-floral-brand" rel="noreferrer noopener">official launch of its first standalone</a> flower and plant brand, Good Little Garden.
With prices starting at $6, the brand offers year-round access to a variety of blooms and greens, catering to both special occasions and everyday moments.
Good Little Garden introduces over 60 varieties of fresh-cut flowers and potted plants to Target's lineup.
Shoppers can now find arrangements featuring roses, tulips, and carnations, as well as potted orchids and succulents, both in stores across the country and via same-day fulfillment options.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44850301/target-under-pressure-from-discretionary-spend-slowdown-mounting-inventory-risk-goldman-sachs-downgrades-stock" rel="noreferrer noopener">Target Under Pressure From Discretionary Spend Slowdown, Mounting Inventory Risk, Goldman Sachs Downgrades Stock</a>
Prices range from $6 for fresh-cut flowers to $15 and up for potted varieties, with seasonal themes that adjust throughout the year to match holidays and seasonal trends.
"When you combine the amazing assortment our team has curated, and everything we've done to ensure we're delivering quality and freshness to stores nationwide, Good Little Garden is making it easier than ever to celebrate any occasion," said executive vice president and chief merchandising officer of food, essentials and beauty, Lisa Roath.
Customers can also shop Good Little Garden products through Target's convenient Drive Up and Order Pickup options. Target Circle 360 members get the added benefit of free same-day delivery for qualifying orders.
Since introducing flowers under its Spritz party brand in 2020, Target has experienced considerable growth in its floral department.
Sales of flowers and plants have surged, tripling in recent years, which has led the company to broaden its selection.
Price Action: TGT shares traded lower by 0.60% at $92.55 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44876406/retail-slowdown-and-tariff-turbulence-hit-leisure-stocks-says-analyst" target="_blank" rel="noreferrer noopener">Retail Slowdown, Tariffs Jolt Leisure Stocks: Analyst Revises Estimates For Topgolf, Harley-Davidson And More</a></li>
</ul>
Photo by bluestork via Shutterstock

Target Rolls Out Standalone Flower Brand 'Good Little Garden'

&nbsp;ASA's Readoption of the Poison Pill Followed the Court's March 28th Ruling that the Pill Violates the Investment Company Act of 1940
ASA's Poison Pill Has Remained in Continuous Effect for More Than 474 Days, Harming Shareholders and Violating Federal Law
Saba Believes the Anti-Shareholder Actions and Unlawful Steps Taken by Chair Mary Joan Hoene and Director William Donovan Underscore the Need for Immediate Board Change
Saba Capital Management, L.P. (together with certain of its affiliates, "Saba"), the largest common shareholder of ASA Gold and Precious Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASA#NYSE">ASA</a>) ("ASA" or the "Fund") with 17.2% ownership of the Fund's outstanding shares, today announced that it has filed a lawsuit in the United States District Court for the Southern District of New York (the "Court") against ASA and the legacy members of its Board of Directors (the "Board") – Mary Joan Hoene and William Donovan – regarding their readoption of an unlawful shareholder rights plan after the Court ruled that the previous shareholder rights plan violated the Investment Company Act of 1940 (the "'40 Act").

Legal

Saba Capital Files Lawsuit Against ASA Gold And Precious Metals And Its Legacy Directors Over Latest Unlawful Poison Pill; Says "ASA's Poison Pill Has Remained in Continuous Effect for More Than 474 Days, Harming Shareholders and Violating Federal Law"

Hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.
The publication, Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes, can be accessed at: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;index=1&amp;md5=93462c6dd5567a9a85f2e87e65dc5785">https://diabetesjournals.org/care/lookup/doi/10.2337/dc24-2841</a>.
CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing's syndrome) in patients with difficult-to-control type 2 diabetes. Part one of the study screened 1,057 patients at 36 sites across the United States. All patients had hemoglobin A1c greater than 7.5 percent, despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. Using a simple, standardized 1-mg dexamethasone suppression test (DST), 24 percent of these patients were found to have hypercortisolism. These findings were first presented at the American Diabetes Association Scientific Sessions in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.corcept.com%2Fnews-releases%2Fnews-release-details%2Fcorcept-announces-presentation-results-prevalence-phase-catalyst&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=June+2024&amp;index=2&amp;md5=12702a0e0a0fa0edd714c70e67cb4916">June 2024</a>.

CORT

Corcept Therapeutics Announces Publication Of Findings From Prevalence Phase Of CATALYST Trial In Diabetes Care

Southern States (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.97 by 6.19 percent. This is a 14.44 percent increase over earnings of $0.90 per share from the same period last year.

Earnings Beats

SSBK

Southern States Q1 Adj EPS $1.03 Beats $0.97 Estimate

Mega Matrix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPU#NYSE">MPU</a>) announced that Yuder Pte. Ltd. ("Yuder"), a indirectly wholly owned subsidiary of it, has signed a Memorandum of Understanding (MOU) with Interactive Films LLC ("Interactive Films"), a subsidiary of Snail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) ("Snail Games"), a leading global independent developer and publisher of interactive digital entertainment. Under this MOU, both parties will leverage their respective strengths to establish a comprehensive collaboration framework for the joint development, production, and global distribution of short dramas, further enhancing their presence in the entertainment industry.

SNAL

Mega Matrix Subsidiary Yuder Signs MOU With Snail Games' Interactive Films To Jointly Develop, Produce, And Distribute Short Dramas Globally

On April 15, 2025, the Board of Directors of American Pacific Corporation (AMPAC), a subsidiary of NewMarket Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>), met and approved a capital investment of up to $100 million to expand its ammonium perchlorate production capabilities in support of growing solid rocket motor demand. This anticipated investment will allow AMPAC to construct an additional production line, increasing capacity by more than 50%. The increased capacity will allow AMPAC to meet the demand of U.S. military and space launch programs, while also addressing the needs of U.S. allies in these critical areas. The project remains subject to approval by NewMarket's board of directors, and is currently scheduled to be completed during 2026.

Newmarket's American Pacific Board Approves Capital Investment Of Up To $100M To Expand Ammonium Perchlorate Production Capabilities In Support Of Growing Solid Rocket Motor Demand

OREM, Utah, April 21, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wcbD5irC69fKfRIuX8183WQn2d5V4CJS_05Xrk_sqVXlPEwcGdkY3vzlkrlMTJ5DJtYmP0UWiskvmGagI5SrPtbdEPFk5tozJyoJkRfL-M0=">Complete Solaria, Inc.</a> d/b/a SunPower ("SunPower" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>), a leading solar technology, services, and installation company, today announced it is rebranding as SunPower. The company's ticker symbol will change from "CSLR" and "CSLRW" to "SPWR" and "SPWRW", respectively, effective April 22, 2025.

CSLR

Complete Solaria, Announces It Will Rebrand As SunPower And Will Change Its Ticker From CSLR to SPWR Effective April 22, 2025

Press Releases

Fastly to Announce Fourth Quarter 2024 Financial Results

New Research Reveals Critical Gaps in Web App and API Security as Attack Complexity Grows

Fastly Announces Fourth Quarter and Full Year 2024 Financial Results

Fastly to Present at Upcoming Investor Conference

Inari Medical, Figs Inc, Fastly, and Ryvyl Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Fastly Research Reveals 93% of Organizations Working to Reduce CISO Liability Risk

Fastly Empowers Organizations to Prioritize Security Without Disrupting End-User Experiences

Fastly Unveils DDoS Attack Insights to Strengthen Protection and Security Transparency

Comments

Fastly

Noticias

Últimas noticias sobre Fastly (NYSE:FSLY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL